RESUMEN
INTRODUCTION AND HYPOTHESIS: The impact of estradiol-based hormone therapy (HT) on the incidence of stress urinary incontinence (SUI) is unknown. Therefore, we compared the use of such HT regimens and tibolone in women with and without SUI. METHODS: The women with a history of SUI operation (N = 15,002) were identified from the Finnish National Hospital Discharge Register, and the control women without such an operation (N = 44,389) from the Finnish Central Population Register. The use of HT was traced from the National Drug Reimbursement Register, and the odd ratios (ORs) with 95% confidence intervals (95% CIs) for SUI were calculated by using the conditional logistic regression analysis. RESULTS: The cases had used any HT more often than the controls. The use of systemic estradiol-only or estradiol-progestin therapy was accompanied by an increased SUI risk (OR 3.8, 95% CI: 3.6-4.0 and OR 2.7, 95% CI: 2.6-2.9 respectively). The use of estradiol with noretisterone acetate showed a higher risk of increase than that with medroxyprogesterone acetate. Age over 55 years at the initiation of systemic HT was accompanied by a higher SUI risk increase than that under 55 years of age. The use of tibolone, an estradiol + levonorgestrel-releasing intrauterine device, or vaginal estradiol also increased the risk. CONCLUSIONS: The use of HT regimens may predispose to the de novo development or worsening of pre-existing SUI. Thus, caution is needed when these regimens are prescribed to women with mild stress-related urine leakage or with established SUI risk factors.
Asunto(s)
Estradiol/efectos adversos , Terapia de Reemplazo de Estrógeno/efectos adversos , Estrógenos/efectos adversos , Norpregnenos/efectos adversos , Incontinencia Urinaria de Esfuerzo/epidemiología , Terapia de Reemplazo de Estrógeno/métodos , Femenino , Finlandia/epidemiología , Humanos , Persona de Mediana Edad , Posmenopausia/efectos de los fármacos , Sistema de Registros , Factores de Riesgo , Incontinencia Urinaria de Esfuerzo/inducido químicamenteRESUMEN
STUDY QUESTION: Does the use of post-menopausal vaginal estradiol (VE) affect the mortality risk for coronary heart disease (CHD) and stroke. SUMMARY ANSWER: The use of VE reduces the risk for cardiovascular mortality. WHAT IS KNOWN ALREADY: A growing number of women use VE for post-menopausal genitourinary symptoms. Although this therapy is intended to have only local effects, estrogen is absorbed into the blood circulation and thus VE use may also have systemic effects. STUDY DESIGN, SIZE, DURATION: We studied a nationwide cohort in Finland 1994-2009 during which post-menopausal women (n = 195 756) initiated the use of VE (age [mean ± SD] 65.7 ± 10.9 years). Follow-up data gathered 1.4 million women-years and we assessed the mortality risk due to CHD (n= 9656) or stroke (n = 4294). PARTICIPANTS/MATERIALS, SETTING, METHODS: The mortality risk in VE users was compared with that in the age-matched background population (standardized mortality ratio; [SMR]; 95% confidence interval) and related to various durations of exposure to VE (1 to ≤3, >3 to ≤5, >5 to ≤10 and >10 years). MAIN RESULTS AND THE ROLE OF CHANCE: The use of VE was accompanied by decreases in the risk for CHD and stroke death. The risk reduction for CHD death was highest for >3 to ≤5 years exposure (SMR 0.64; 0.57-0.70) and for stroke for >5 to ≤10 years exposure (SMR 0.64; 0.57-0.72). The risk reductions for both CHD and stroke mortality were detected in all age groups with the highest risk reduction being in women aged 50-59 years (SMR 0.43; 0.19-0.88 and SMR 0.21; 0.06-0.58, respectively). LIMITATIONS, REASONS FOR CAUTION: Our series lack a placebo arm and thus, may harbor a healthy woman bias. Moreover, data on clinical variables such as weight, smoking, blood pressure and family background were unobtainable for this study. Women using both VE and systemic hormone therapy (HT) were included in the comparator background population. This should not cause any significant error because the proportion of women using VE or other HT was modest (<10% in age-matched population) and because the use of systemic HT also reduces death risks in the same population. Our data cannot be directly applied for local regimens containing conjugated equine estrogens, because they are absorbed differently and may show effects that differ from those of estradiol. WIDER IMPLICATIONS OF THE FINDINGS: In 1000 women using VE for up to 10 years, a maximum of 24 fewer CHD deaths and 18 fewer stroke deaths is likely to occur. STUDY FUNDING/COMPETING INTERESTS: This work was supported by unrestricted grants from the Päivikki and Sakari Sohlberg Foundation, the Emil Aaltonen Foundation, the Finnish Medical Foundation, Finska Läkaresällskapet, the Orion Farmos Research Foundation, the Paavo Nurmi Foundation and a special governmental grant for health sciences research. The funding sources had no role in the study design, data handling or manuscript preparation. EPID Research is a company that performs financially supported studies for several pharmaceutical companies. Dr Korhonen, Dr Hoti and MSc Vattulainen, employed by Epid Research, report financial activities from several other pharmaceutical companies outside the submitted work. Dr Mikkola has been a speaker and/or received consulting fees from Mylan and Novo Nordisk. Dr Tuomikoski has been a speaker and/or received consulting fees from Orion and Mylan. The remaining authors report no conflict of interest.
Asunto(s)
Fármacos Cardiovasculares/uso terapéutico , Enfermedad Coronaria/prevención & control , Estradiol/uso terapéutico , Estrógenos/uso terapéutico , Enfermedades Urogenitales Femeninas/tratamiento farmacológico , Posmenopausia , Accidente Cerebrovascular/prevención & control , Anciano , Fármacos Cardiovasculares/administración & dosificación , Estudios de Cohortes , Enfermedad Coronaria/epidemiología , Enfermedad Coronaria/mortalidad , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/uso terapéutico , Prescripciones de Medicamentos , Estradiol/administración & dosificación , Estrógenos/administración & dosificación , Femenino , Finlandia/epidemiología , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Sistema de Registros , Factores de Riesgo , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/mortalidad , Cremas, Espumas y Geles VaginalesRESUMEN
Data on the possible impact of postmenopausal hormone therapy (HT) on the incidence of rare primary fallopian tube carcinoma (PFTC) are scarce. Therefore, we conducted a nationwide case-control study analyzing the association between the use of different HTs and PFTC. All women aged 50 years or older with an incident PFTC (n = 360) during 1995-2007 were identified from the Finnish Cancer Registry. For each case of PFTC, ten age- and place of residence-matched controls were selected from the Finnish National Population Register, which also provided information on parity. Data on HT purchases were received from the Prescription Register, and data on hysterectomies and sterilizations from the National Care Register. Controls with a salpingectomy before the PFTC diagnosis of the respective case were excluded. The PFTC risk in relation to different HTs was estimated with a conditional logistic regression model, adjusted for parity, age at last delivery, hysterectomy and sterilization. The use for five years or more of estradiol combined with levonorgestrel-releasing-intrauterine system (odds ratio 2.84, 95% confidence interval 1.10-7.38) and sequential estradiol-progestin therapy (EPT; 3.37; 2.23-5.08) were both linked with increases in the risk of PFTC, while the risk with use of estradiol-only therapy or continuous EPT was not statistically significantly increased. The OR for the use of tibolone for one year or more was 1.56 (0.55-4.41). The use of HT is related to an increased risk of PFTC, particularly when a progestin component is intrauterine or systemic progestin is given in sequential manner.
Asunto(s)
Estradiol/efectos adversos , Terapia de Reemplazo de Estrógeno/efectos adversos , Neoplasias de las Trompas Uterinas/inducido químicamente , Neoplasias de las Trompas Uterinas/epidemiología , Levonorgestrel/efectos adversos , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Quimioterapia Combinada/efectos adversos , Estradiol/administración & dosificación , Femenino , Finlandia/epidemiología , Humanos , Levonorgestrel/administración & dosificación , Modelos Logísticos , Persona de Mediana Edad , Posmenopausia , Factores de RiesgoRESUMEN
OBJECTIVE: To study the possible association between menopausal hot flushes and bone mineral density. DESIGN: Observational study. SETTING: University clinic. POPULATION: Healthy women (n = 143) with or without hot flushes, 6-36 months postmenopausal after participating in a 6-month hormone therapy trial. METHODS: The women prospectively recorded the number and severity of hot flushes for 2 weeks. Bone mineral density in lumbar and hip bones was measured with dual-energy X-ray absorptiometry at recruitment and reassessed in 114 women approximately 6.2 years later. MAIN OUTCOME MEASURES: Hot flushes and bone mineral density. RESULTS: At recruitment, hot flushes were absent in 22 women, mild in 32, moderate in 28, and severe in 61. Lumbar bone mineral densities in non-flushing women (1.130 ± 0.022 g/cm(2) ; mean ± SEM), and in those with mild (1.088 ± 0.024 g/cm(2) ), moderate (1.082 ± 0.030 g/cm(2) ) or severe (1.102 ± 0.019 g/cm(2) ) hot flushes did not differ, nor were there differences in hip bone mineral densities between the four study groups. During the follow-up, lumbar bone mineral density decreased by a mean of 0.4 ± 0.1% a year in women not using hormone therapy, and increased by 0.1 ± 0.2% a year in hormone therapy users (p = 0.019). The respective non-significant changes in left and right total hip bone mineral densities were - -0.6 ± 0.01 and -1.0 ± 0.1 for the non-users, and -0.4 ± 0.1 and -0.6 ± 0.2 for hormone therapy users. These changes in bone mineral density bore no relation to the hot flush status at baseline. CONCLUSION: In recently menopausal women, hot flushes do not appear to determine bone mass density.
Asunto(s)
Densidad Ósea/fisiología , Sofocos/fisiopatología , Femenino , Cadera/fisiopatología , Humanos , Persona de Mediana Edad , Posmenopausia , Estudios Prospectivos , Columna Vertebral/fisiopatología , Factores de TiempoRESUMEN
Postmenopausal hormone therapy (HT) associates with an increased risk of ovarian cancer, but its' influence on tumor histology is not as well known. Therefore, we evaluated the effect of various types of HT on the risk of epithelial ovarian cancer by histological subtype. All Finnish women diagnosed with ovarian cancer (n = 3,958) aged over 50 during 1995-2007 were identified from the Finnish Cancer Registry. For each case, three controls, matched for age and place of residence, were recruited from the Finnish National Population Register, which also provided data on parity and ages at deliveries. After exclusion of controls with oophorectomy, 11,325 controls remained. The prescription register provided HT use from age 50. Odds ratios (OR) for different HTs were estimated by conditional logistic regression: adjusted for parity, ages at deliveries and hysterectomy. Estradiol-only therapy use for 5 years or more associated with an increased risk (OR 1.45; 95% confidence interval 1.20-1.75) of a serous subtype, but with a decreased risk of mucinous subtype (0.35; 0.19-0.67). Use of sequential estradiol-progestin therapy (EPT) for 5 years or more associated with an increase in overall ovarian cancer risk (1.35; 1.20-1.63) and with an increase in the endometrioid subtype (1.88; 1.24-2.86) particularly. Continuous EPT, estradiol + levonorgestrel-releasing intrauterine system or tibolone had no effect on overall ovarian cancer risk. In conclusion, only sequential EPT use for 5 years or more associates with an increased risk of overall ovarian cancer. Furthermore, HT regimens differ significantly in their association with various histological types of ovarian cancer.
Asunto(s)
Terapia de Reemplazo de Estrógeno/efectos adversos , Neoplasias Ováricas/epidemiología , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Anticonceptivos Femeninos/uso terapéutico , Estradiol/uso terapéutico , Moduladores de los Receptores de Estrógeno/uso terapéutico , Estrógenos/uso terapéutico , Femenino , Finlandia/epidemiología , Humanos , Levonorgestrel/uso terapéutico , Persona de Mediana Edad , Norpregnenos/uso terapéutico , Neoplasias Ováricas/inducido químicamente , Posmenopausia , Progestinas/uso terapéutico , Sistema de Registros , RiesgoRESUMEN
OBJECTIVE: Both smoking and the release of nitric oxide (NO) in the uterine cervix are determinants for high-risk human papillomavirus (hrHPV) infection. We compared the cervical NO release between smoking and non-smoking women with and without hrHPV infection. DESIGN: Open clinical cohort study. SETTING: University Hospital in Finland. POPULATION: One hundred and twenty-five smoking and 301 non-smoking women, with (n = 244) and without (n = 182) hrHPV infection. In total, 264 women showed cytological and/or histological cervical epithelial changes. METHODS: The presence of hrHPV was tested by an HPV DNA test and the release of NO was assessed from NO metabolites in the cervical fluid by the Griess reaction. MAIN OUTCOME MEASURES: The difference in cervical NO release between smoking and non-smoking women with and without hrHPV. RESULTS: Infection with hrHPV in smokers (70%) was more frequent (p = 0.001) than in non-smokers (52%). As a whole, smoking was accompanied by a 35% decrease (p = 0.04) in NO release in hrHPV-infected women (35.9 µmol/L, 95% confidence interval 27.0-44.2) compared with non-smoking hrHPV- infected women (48.3 µmol/L, 95% confidence interval 38.0-56.2). No difference in NO release between smokers and non-smokers was seen in women with healthy cervical epithelium, but smoking was accompanied by a suppressed (26%) NO release (p = 0.03) in women with either cytological or histological changes. CONCLUSIONS: Smoking may suppress NO release in the uterine cervix in women with hrHPV infection.
Asunto(s)
Cuello del Útero/metabolismo , Óxido Nítrico/metabolismo , Infecciones por Papillomavirus/metabolismo , Fumar/metabolismo , Adolescente , Adulto , Cuello del Útero/patología , Estudios de Cohortes , ADN Viral/genética , Epitelio/metabolismo , Femenino , Humanos , Persona de Mediana Edad , Papillomaviridae/genética , Papillomaviridae/metabolismo , Neoplasias del Cuello Uterino/patología , Adulto Joven , Displasia del Cuello del Útero/patologíaRESUMEN
OBJECTIVE: To study perinatal mortality associated with placental abruption. DESIGN: Retrospective population study using the Finnish Hospital Discharge Register and Medical Birth Register data. SETTING: Finland, 1987-2005. POPULATION: Pregnancies with placental abruption and all other births without placental abruption. METHODS: The national Hospital Discharge Register and Medical Birth Register were used to identify all pregnancies with placental abruption. Demographic data and delivery outcomes were collected retrospectively. Perinatal mortality associated with placental abruption was compared with that in other births. Potential risk factors were analysed. MAIN OUTCOME MEASURES: Perinatal mortality in placental abruption. RESULTS: The study consisted of 618 735 women with 1.14 million pregnancies, 4336 of whom had placental abruption. Overall perinatal mortality with abruption was 119 per 1000 births. Placental abruption explained 7% of all perinatal deaths. The mortality among singleton births (125 per 1000) was higher than among multiple births (40 per 1000). The majority of deaths (77%) occurred in utero. Singleton perinatal mortality with abruption decreased from 173 per 1000 in 1987-1990 to 98 per 1000 in 2000-2005 (p < 0.001). In singleton births at <32 gestational weeks, overall perinatal mortality was high (345 per 1000) and was not increased by placental abruption. Prematurity, low birthweight, male fetal sex and maternal smoking were independent risk factors for placental abruption-related perinatal mortality. CONCLUSIONS: Although mortality associated with placental abruption decreased during the study period, placental abruption still remains an important cause of perinatal mortality.
Asunto(s)
Desprendimiento Prematuro de la Placenta/mortalidad , Adulto , Peso al Nacer , Femenino , Finlandia/epidemiología , Edad Gestacional , Humanos , Recién Nacido , Masculino , Análisis Multivariante , Mortalidad Perinatal/tendencias , Embarazo , Embarazo Múltiple/estadística & datos numéricos , Nacimiento Prematuro/mortalidad , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Fumar , Adulto JovenRESUMEN
The aim of this study was to evaluate the association of postmenopausal estradiol-progestagen therapy (EPT) with the risk for precancerous lesions, squamous cell carcinoma and adenocarcinoma of the uterine cervix. All Finnish women who had used EPT in 1994-2008 for at least 6 months (n = 243,857) at the age of 50 years or more were identified from the national Medical Reimbursement Registry and linked to the Finnish Cancer Registry. The incidence of cervical precancerous or cancerous lesions among EPT users was compared to that in the background population. There were 210 EPT users with squamous lesions (178 with precancerous and 32 with cancer) and 79 EPT users with glandular lesions (14 precancerous and 65 adenocarcinomas). The ever use of EPT did not associate with the incidence of precancerous lesions, but the risk for squamous cell carcinoma decreased (standardized incidence ratio 0.41; 95% confidence interval 0.28-0.58) and that for adenocarcinoma increased (1.31; 1.01-1.67). After the use of EPT for 5 years, the risk for squamous cell carcinoma decreased (0.34; 0.16-0.65), and the risk for adenocarcinomas increased (1.83; 1.24-2.59). The prolonged use of EPT is associated with the occurrence of cervical malignancies. If the association would be a causal one, the use for 5+ years among 10,000 women followed for 10 years would mean about two to three fewer cases of cervical squamous cell carcinoma but about two extra cases with adenocarcinoma.
Asunto(s)
Estradiol/administración & dosificación , Posmenopausia , Progestinas/administración & dosificación , Neoplasias del Cuello Uterino/inducido químicamente , Estradiol/efectos adversos , Femenino , Finlandia/epidemiología , Humanos , Incidencia , Persona de Mediana Edad , Progestinas/efectos adversos , Factores de RiesgoRESUMEN
The authors conducted a nationwide cohort study to evaluate the association between postmenopausal hormone therapy and meningioma incidence in Finland. All women who had used hormone therapy at least for 6 months at the age of 50 years or older during 1994-2009 were included. Women who had used postmenopausal hormone therapy were identified from the medical reimbursement register of the Social Insurance Institution (131,480 estradiol users and 131,248 estradiol-progestin users), and meningioma cases were identified from the Finnish Cancer Registry. During the average 9 years of follow-up, 289 estradiol users and 196 estradiol-progestin users were diagnosed with meningioma. Ever use of estradiol-only therapy was associated with an increased risk of meningioma (standardized incidence ratio = 1.29, 95% confidence interval: 1.15, 1.44). Among women who had been using estradiol-only therapy for at least 3 years, the incidence of meningioma was 1.40-fold higher (95% confidence interval: 1.18, 1.64; P < 0.001) than in the background population. In contrast, this risk was not increased in users of combination therapy (standardized incidence ratio = 0.93, 95% confidence interval: 0.80, 1.06). There was no difference in risk between continuous and sequential use of hormone therapy. Estradiol-only therapy was accompanied with a slightly increased risk of meningioma.
Asunto(s)
Estradiol/efectos adversos , Terapia de Reemplazo de Estrógeno/efectos adversos , Estrógenos/efectos adversos , Neoplasias Meníngeas/inducido químicamente , Meningioma/inducido químicamente , Progestinas/efectos adversos , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Combinación de Medicamentos , Femenino , Finlandia/epidemiología , Humanos , Incidencia , Neoplasias Meníngeas/epidemiología , Meningioma/epidemiología , Persona de Mediana Edad , Distribución de Poisson , Sistema de Registros , Análisis de Regresión , RiesgoRESUMEN
OBJECTIVE: Primary fallopian tube carcinoma (PFTC) is a rare malignancy and only sparse data exist on its possible association with postmenopausal hormone therapy (HT). We therefore studied this association in a nationwide cohort of Finnish HT users. METHODS: All women> 50 years using systemic estradiol-only therapy (ET) (n=117,820 hysterectomized women) or estradiol-progestin therapy (EPT) (n=247,781 nonhysterectomized women) for ≥ 6 months during 1994-2008 were identified from the national medical reimbursement register. The incidence of PFTC in HT users was compared to that in the comparable background population (standardized incidence ratio, SIR, with 95% confidence interval, CI). RESULTS: A total of 160 cases of PFTC were encountered in users of ET (n=34) or EPT (n=126). The use of EPT ≥ 5 years was accompanied by an increased risk for PFTC (SIR 2.15; 95% CI 1.66-2.72). The SIR increased further to 3.36 (95% CI 2.02-5.24) when EPT use lasted ≥ 10 years. The EPT-related risk for PFTC was restricted to the sequential EPT and it was not seen for continuous EPT. Two leading progestins in EPT, norethisterone acetate and medroxyprogesterone acetate, associated with comparable risk elevations. ET use was not associated with the risk for PFTC. CONCLUSIONS: The long-term, sequential use of EPT associates with an increased risk for PFTC. In absolute terms, 4 additional cases of PFTC would be detected in 10-year follow-up of 10,000 women who have used EPT for at least 5 years.
Asunto(s)
Terapia de Reemplazo de Estrógeno/estadística & datos numéricos , Neoplasias de las Trompas Uterinas/epidemiología , Estudios de Cohortes , Estradiol/administración & dosificación , Terapia de Reemplazo de Estrógeno/efectos adversos , Neoplasias de las Trompas Uterinas/inducido químicamente , Femenino , Finlandia/epidemiología , Humanos , Histerectomía , Persona de Mediana Edad , Progestinas/administración & dosificaciónRESUMEN
OBJECTIVES: To investigate the impact of pre-eclampsia on the future cardiovascular risk in Finnish women DESIGN: A registry-based nationwide controlled cohort study. SETTING: Women hospitalised for pre-eclampsia in 1969-1993 and control women with a history of normotensive pregnancies followed from the pre-eclampsia diagnosis until 2019 for cardiovascular outcomes. PARTICIPANTS: 31 688 women with and 91 726 control women without a history of pre-eclampsia. PRIMARY OUTCOME MEASURES: Incidences of and deaths from ischaemic heart disease (IHD), myocardial infarction (MI) and stroke. RESULTS: In total, 25 813 (81.5%) women had pre-eclampsia without severe features, 4867 (15.4%) had pre-eclampsia with severe features and 1006 (3.2%) women developed eclampsia. Women with a history of pre-eclampsia showed elevated risks for IHD (HR 1.52, 95% CI 1.44 to 1.59), MI (HR 1.66, 95% CI 1.52 to 1.81) and stroke (HR 1.40, 95% CI 1.32 to 1.48). The risks for death from IHD (HR 1.50, 95% CI 1.28 to 1.75), MI (1.63, 95% CI 1.30 to 2.05) and stroke (1.44, 95% CI 1.03 to 2.01) were also elevated. Pre-eclampsia with severe features or eclampsia was accompanied with 15% higher IHD risk, 19% higher MI risk and 26% higher stroke risk than pre-eclampsia without severe features. The highest risk elevations of 30% for IHD, 32% for MI and 30% for stroke were observed in women with recurrent pre-eclampsia (n=4180). CONCLUSION: Pre-eclampsia-related significant elevations in CVD risks of Finnish women with inherently high risk for these diseases were of the same magnitude as reported previously from other countries. Thus, women with a history of pre-eclampsia should be screened and treated early for modifiable cardiovascular risk factors.
Asunto(s)
Enfermedades Cardiovasculares , Enfermedad de la Arteria Coronaria , Eclampsia , Infarto del Miocardio , Isquemia Miocárdica , Preeclampsia , Accidente Cerebrovascular , Embarazo , Humanos , Femenino , Masculino , Preeclampsia/epidemiología , Estudios de Cohortes , Enfermedades Cardiovasculares/epidemiología , Eclampsia/epidemiología , Factores de Riesgo , Finlandia/epidemiología , Isquemia Miocárdica/epidemiología , Infarto del Miocardio/epidemiología , Factores de Riesgo de Enfermedad Cardiaca , Accidente Cerebrovascular/epidemiologíaRESUMEN
This study evaluates the effect of different modes of estradiol-progestagen therapy (EPT) regimens on the postmenopausal endometrial cancer risk in Finland. Women diagnosed with endometrial cancer in 1995-2007 at the age of 50-80 years were identified from the Finnish Cancer Registry (N = 7,261). For each case, three age-matched controls were retrieved from the Finnish Population Register. The use of EPT since 1994 was ascertained from the national Medical Reimbursement Register. Odds ratios (ORs) for different EPT regimens were calculated with conditional logistic regression analysis, adjusted for parity and ages at the deliveries. For use of <5 years, the OR for sequential EPT was 0.67 (95% confidence interval 0.52-0.86), for continuous EPT 0.45 (0.27-0.73), and for estradiol plus levonorgestrel-releasing intrauterine device system (LNG-IUS) 0.39 (0.17-0.88). A decreased risk persisted for the use of continuous EPT and estradiol plus LNG-IUS of up to 10 years. The use of long-cycle EPT showed a tendency toward an elevated risk both for exposure of <5 years (1.40; 0.82-2.38) and for estimated use of >5 years (1.63; 1.12-2.38). For an estimated exposure of >10 years, the risk for endometrial cancer was elevated for both users of long-cycle EPT (2.95; 2.40-3.62) and sequential EPT (1.38; 1.15-1.66). Norethisterone acetate and medroxyprogesterone acetate as parts of EPT did not differ in their endometrial cancer risk. The use of tibolone showed no endometrial risk. The use of sequential and long-cycle EPT is associated with an increased risk of endometrial cancer, whereas the use of continuous EPT or estradiol plus LNG-IUS shows a decreased risk.
Asunto(s)
Neoplasias Endometriales/etiología , Estradiol/metabolismo , Progestinas/metabolismo , Factores de Edad , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Neoplasias Endometriales/inducido químicamente , Estradiol/efectos adversos , Terapia de Reemplazo de Estrógeno/efectos adversos , Femenino , Finlandia , Humanos , Persona de Mediana Edad , Oportunidad Relativa , Posmenopausia , Sistema de Registros , RiesgoRESUMEN
Nitric oxide may serve as one cofactor for human papillomavirus (HPV)-induced development of cervical cancer. Therefore, we first assessed the levels of cervical fluid nitric oxide metabolite (NOx) in 283 women with and without high-risk (hr) HPV. The NOx level in women with hr HPV (48.4 µmol/L [95% CI: 39.4-56.6], n = 199) was higher (p < 0.001) than that in women without hr HPV (24.6 µmol/L [95% CI: 19.1-38.7], n = 84). Second, we evaluated if cervical fluid NOx levels could predict the persistence of hr HPV. Therefore, we followed up 113 women with detectable hr HPV without any treatment for 12 mo and repeated hr HPV test. High-risk HPV persisted in 72 women (64%) and disappeared in 41 women (36%). The median basal levels of NOx were higher (p = 0.02) in women with persistent hr HPV (56.9 µmol/L [95% CI: 48.7-81.0]) compared to those with eradicated hr HPV (37.7 µmol/L [95% CI: 27.0-58.0]). The NOx level higher than the 75th percentile (>87.0 µmol/L) predicted hr HPV persistence (OR = 4.1 [95% CI: 1.3-13.1]). This cutoff level of NOx showed 33% sensitivity and 90% specificity in predicting the persistence of hr HPV, but it failed to predict cytological progression or regression in 12 mo. In conclusion, high cervical fluid NOx appears to be connected to the persistence of hr HPV, but the low predictive capacity of NOx prevents its clinical use at this phase.
Asunto(s)
Alphapapillomavirus/aislamiento & purificación , Cuello del Útero/metabolismo , Óxido Nítrico/metabolismo , Adolescente , Adulto , Cuello del Útero/virología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
OBJECTIVE: Insufficient data exist on the effect of postmenopausal hormone therapy as the risk factor for uterine sarcomas. We therefore evaluated the association of estradiol-progestin therapy (EPT) with the risk of uterine sarcoma in nation-wide cohort study. METHODS: All Finnish women (>50 years of age) who had used EPT during the years 1994-2008 for at least 6 months (n=243,857) were identified from the national Medical Reimbursement Registry. Their incidence of uterine stromal and leiomyosarcoma among the EPT users was compared to that in the background population with the aid of the Finnish Cancer Registry. RESULTS: A total of 76 uterine sarcomas were encountered in the EPT cohort; 45 (59%) were leiomyosarcomas, 24 (32%) stromal sarcomas and 7 (9%) other sarcomas. The exposure to EPT for less than 5 years did not associate with significant rises in the sarcoma risk but longer exposure was accompanied with significant risk elevations for all uterine sarcomas: the standardized incidence ratio (SIR) for 5-10 years of use was 2.0, 95% confidence interval (CI) 1.4-2.9 and for ≥10 years of use 3.0 (1.3-5.9): the SIRs were highest for leiomyosarcoma. The sequential and continuous uses of progestin were associated with similar increased SIRs for uterine sarcoma. CONCLUSIONS: The use of EPT for 5 years or more is associated with an increased risk for uterine sarcomas. This turns to an absolute excess risk of 2-3 extra uterine sarcoma cases per 10,000 long-time EPT users followed for 10 years.
Asunto(s)
Estradiol/efectos adversos , Terapia de Reemplazo de Estrógeno/efectos adversos , Progestinas/efectos adversos , Sarcoma/inducido químicamente , Neoplasias Uterinas/inducido químicamente , Anciano , Estudios de Cohortes , Femenino , Humanos , Leiomiosarcoma/inducido químicamente , Persona de Mediana Edad , Riesgo , Factores de TiempoRESUMEN
OBJECTIVE: To compare cervical fluid nitric oxide release in women with and without Chlamydia trachomatis and high-risk human papillomavirus infection (hrHPV). DESIGN: An open clinical study. SETTING: University Hospital of Helsinki. POPULATION: Thirty-nine women with (n=21) and without C. trachomatis (n=18). METHODS: Chlamydia trachomatis and/or hrHPV were studied by using specific RNA- and DNA-based tests. Levels of cervical fluid nitric oxide metabolite (NOx) were assessed by the Griess reaction. MAIN OUTCOME MEASURES: The difference in cervical fluid NOx between women with and without C. trachomatis and hrHPV. RESULTS: Fourteen (67%) C. trachomatis-infected women and three (17%) noninfected women had concomitant hrHPV. The level of cervical fluid NOx in women with C. trachomatis (median 37.5 µmol/l, 95% confidence interval 26.1-50.9) was higher (p=0.02) than that in C. trachomatis-noninfected women (median 19.7 µmol/L, 95% confidence interval 5.6-30.0). The presence of hrHPV did not associate with any difference in NOx levels between C. trachomatis-infected or -noninfected women. CONCLUSIONS: Chlamydia trachomatis was associated with increased release of nitric oxide metabolites in the uterine cervix. This stimulus was stronger than that of hrHPV, because no additional rise in NOx was seen in women with concomitant C. trachomatis and hrHPV infection.
Asunto(s)
Cuello del Útero/metabolismo , Infecciones por Chlamydia/metabolismo , Óxido Nítrico/metabolismo , Infecciones por Papillomavirus/metabolismo , Adolescente , Adulto , Chlamydia trachomatis/metabolismo , Femenino , Humanos , Persona de Mediana Edad , Papillomaviridae/metabolismoRESUMEN
Breast cancer is a heterogenous disease and hormonal factors are involved. Since national differences exist in the use of postmenopausal hormone therapy (HT) and other risk factors, associations between HT and breast cancer should be studied nationally. In Finland, estrogen-progestin therapy is associated with higher breast cancer risk than estrogen-only therapy. Also tibolone and levonorgestrel releasing intauterine device combined with estrogen are accompanied with an increased risk of breast cancer. Hormone therapy possibly promotes the growth of the existing undetectable cancer.
Asunto(s)
Neoplasias de la Mama/inducido químicamente , Neoplasias de la Mama/epidemiología , Terapia de Reemplazo de Estrógeno/efectos adversos , Posmenopausia , Anciano , Anticonceptivos Femeninos/efectos adversos , Moduladores de los Receptores de Estrógeno/efectos adversos , Femenino , Finlandia/epidemiología , Humanos , Dispositivos Intrauterinos/efectos adversos , Levonorgestrel/efectos adversos , Persona de Mediana Edad , Norpregnenos/efectos adversos , Factores de RiesgoRESUMEN
We examined the associations between various doses and routes of administration of norethisterone acetate (NETA) in estrogen-progestagen therapy (EPT) and the risk of breast cancer in Finland. All Finnish women with first invasive breast cancer diagnosed between the ages of 50-62 during 1995-2007 (n = 9,956) were identified from the Finnish Cancer Registry. For each case, 3 controls of the same age were retrieved from the Finnish Population Register. The use of estradiol+NETA-therapy by the cases and controls was traced from the national Medical Reimbursement Registry. The data were analyzed with multivariate conditional logistic regression, adjusting for parity, age at the first birth, and health care district. The continuous mode of NETA use tended to be associated with a higher rate ratio for breast cancer than the sequential use. The use of continuous "low" dose (NETA 0.5 mg + estradiol 1.0 mg) was associated with an increased rate ratio of breast cancer already in less than 3 years of use (odds ratio 1.94; 95% confidence interval 1.39-2.70) while a risk elevation for "high" dose (NETA 1.0 mg + estradiol 2.0 mg) was seen after 3 years use (1.71; 1.51-2.54). Oral and transdermal use of NETA were accompanied with comparable risks for breast cancer. In conclusion, the dose or route of administration of NETA in EPT do not modify the risks for breast cancer.
Asunto(s)
Neoplasias de la Mama/epidemiología , Terapia de Reemplazo de Estrógeno , Noretindrona/análogos & derivados , Estudios de Casos y Controles , Femenino , Finlandia/epidemiología , Humanos , Persona de Mediana Edad , Análisis Multivariante , Noretindrona/administración & dosificación , Acetato de Noretindrona , Sistema de RegistrosRESUMEN
The purpose of this study was to evaluate the association between postmenopausal hormone therapy (HT) and the risk for breast cancer in recently postmenopausal Finnish women. All Finnish women with first invasive breast cancer diagnosed between the ages of 50 and 62 years during 1995-2007 (n = 9,956) were identified from the Finnish Cancer Registry. For each case, 3 controls of the same age were retrieved from the Finnish Population Register. The cases and controls were linked to the national medical reimbursement register to assess the use of HT. The odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer were calculated with conditional logistic regression analysis, adjusting for parity, age at the first birth and health care district. Estradiol-only therapy (991 users with breast cancer, n) or oral progestagen (n = 138) was not accompanied by an increased risk. Estradiol-progestagen therapy (EPT) (n = 1,731) was associated with an elevated risk in the whole series (OR 1.36; 95% CI 1.27-1.46). The risk became detectable in less than 3 years of use. Continuous EPT use tended to be associated with a higher risk for breast cancer than the sequential EPT use. The use of tibolone (n = 80) (1.36; 1.15-1.96), a levonorgestrel-releasing intrauterine system (LNG-IUS) alone (n = 154) (1.45; 1.97-1.77) or as a complement to estradiol (n = 137) (2.15; 1.72-2.68) was also associated with an increased risk. The association between HT use and the risk for breast cancer shows a large variation between various forms of HT, and also the use of LNG-IUS may carry a risk.
Asunto(s)
Neoplasias de la Mama/epidemiología , Terapia de Reemplazo de Estrógeno/efectos adversos , Posmenopausia , Neoplasias de la Mama/etiología , Estudios de Casos y Controles , Estradiol/efectos adversos , Terapia de Reemplazo de Estrógeno/métodos , Femenino , Finlandia/epidemiología , Humanos , Dispositivos Intrauterinos Medicados/efectos adversos , Persona de Mediana Edad , Oportunidad Relativa , Progestinas/efectos adversos , Factores de RiesgoRESUMEN
OBJECTIVE: smoking is an important risk factor for placental abruption with strong dose-dependency. Pregnant smokers often underreport tobacco use which can be objectively assessed by measuring serum cotinine levels. We examined the accuracy between self-reported smoking habits and early pregnancy serum cotinine levels in women with or without placental abruption. DESIGN: retrospective case-control study. SETTING: university Hospital. POPULATION: a total of 175 women with placental abruption and 370 control women. METHODS: serum samples collected during the first trimester were analyzed for serum cotinine levels. Cotinine concentration over 15 ng/ml was considered as the cutoff indicating active smoking. Smoking habits of the women and their partners were recorded at the same visit. MAIN OUTCOME MEASURE: placental abruption. RESULTS: of the cases of women with placental abruption, 27.4% reported smoking compared with 14.3% of the controls (p < 0.001). Based on serum cotinine levels, 30.3% of the case women and 17.6% of the control women were considered smokers (p = 0.003). Serum cotinine levels among smokers were higher in the abruption group than in the control group (median 229.5 ng/ml (interquartile range 169.8-418.1) vs. 153.5 ng/ml (56.6-241.4), p = 0.002). Self-reported number of cigarettes smoked daily correlated well with the cotinine levels (r = 0.68, p < 0.001). Of the women reporting as nonsmokers, approximately 7% were considered smokers based on cotinine testing. CONCLUSION: pregnant women with subsequent placental abruption are heavier smokers than pregnant control women. Self-reported smoking habits correlate well with serum cotinine levels in Finland. Therefore, self-reported smoking can be considered as a risk marker for placental abruption.
Asunto(s)
Desprendimiento Prematuro de la Placenta/sangre , Desprendimiento Prematuro de la Placenta/epidemiología , Cotinina/sangre , Recien Nacido Prematuro , Resultado del Embarazo , Fumar/sangre , Fumar/epidemiología , Desprendimiento Prematuro de la Placenta/etiología , Adolescente , Adulto , Puntaje de Apgar , Estudios de Casos y Controles , Causalidad , Distribución de Chi-Cuadrado , Comorbilidad , Bases de Datos Factuales , Femenino , Edad Gestacional , Hábitos , Hospitales Universitarios , Humanos , Incidencia , Recién Nacido , Embarazo , Valores de Referencia , Medición de Riesgo , Autorrevelación , Fumar/efectos adversos , Estadísticas no Paramétricas , Adulto JovenRESUMEN
OBJECTIVE: Placental abruption is an important cause of preterm birth, and perinatal morbidity and mortality. Although more common with male fetuses, outcomes have not been evaluated by sex. Our aim was to find out whether short-term morbidity differs by infant sex in cases with placental abruption and in controls. DESIGN: Register-based case-control study. SETTING: National Hospital Discharge Register and Medical Birth Register data 1987-2005. POPULATION: The study population consisted of 4,081 women with placental abruption and singleton infant. Three control women without placental abruption were selected for each case matched by maternal age, parity, year of birth, and hospital district. A total of 3,688 cases and 12,695 controls had liveborn infants. METHODS: Data on pregnancy, delivery, and perinatal outcomes were collected. MAIN OUTCOME MEASURE: Placental abruption. RESULTS: The sex ratio (proportion of male) of cases was 0.548 and of controls 0.516 (p = 0.001). Compared with females, male fetuses in the placental abruption group were born earlier (p = 0.018). Compared with controls, cases with placental abruption were born earlier (p < 0.001), had lower birthweight (p < 0.001), were more often growth restricted (p < 0.001), had lower Apgar scores (p < 0.001) and pH (p < 0.001). Newborn cases needed special care, respirator treatment, antimicrobial and phototherapy more often (p < 0.001) than controls. There was no difference in perinatal outcomes between female and male infants in the placental abruption group. CONCLUSIONS: Placental abruption occurred earlier in pregnancy with male fetal sex but otherwise the outcomes were similar. Compared with controls newborns in the placental abruption group had a worse outcome.